I agree. There is no way Gilead is not looking at

I agree. There is no way Gilead is not looking at mono if they think it is possible. I believe it is possible and FDA approval for a p3 mono pivotal trial starting will go a long way to show that. Do you notice NP saying the ex Gilead high ranking officer told him that a once a month sq would dominate the market (or something similar) We have quoted the current management saying the same. Yes one main disadvantage is leronlimab is only for R5, but with R5 having 70% of the population and almost 100% in naive patients, it has a very attractive market potential. A lot of statements NP makes publically I feel is not intended for shareholders, but potential partners. He is talking next week about the once a month possibility. Combo will be once a week, but maybe PrEP will go with once a month. I assume mono would need more testing before switching to once a month, so I’m guessing at this point they continue with once a week for that trial, maybe others have opinions here? But the PrEP study should give them some good data to build the once a month foundation, if they go that route.